Daewoong Pharmaceutical's Pexuclu Approved in Indonesia... Accelerating Entry into Southeast Asian Market

Daewoong Pharmaceutical's gastroesophageal reflux disease treatment Pexuclu (ingredient name: fexuprazan) has obtained marketing authorization in Indonesia. With entry into the largest pharmaceutical market in Southeast Asia, the company is accelerating its global expansion.

Product image of Pexucla, a gastroesophageal reflux disease treatment. Daewoong Pharmaceutical

원본보기 아이콘

On April 17, Daewoong Pharmaceutical announced that Pexuclu 40mg has been approved in Indonesia for the indication of treating erosive gastroesophageal reflux disease.

Indonesia, with a population of about 280 million, is the largest market in Southeast Asia. It is considered a priority country for global pharmaceutical companies when entering the region. According to market research firm IQVIA, as of 2024, the Indonesian anti-ulcer drug market is valued at approximately USD 154.95 million (about KRW 22.92 billion), showing an average annual growth rate of 6%.

Pexuclu is a potassium-competitive acid blocker (P-CAB). It is characterized by a rapid onset of action and ease of administration compared to conventional proton pump inhibitors (PPIs).

Daewoong Pharmaceutical is working to expand both local prescriptions and indications. The company is conducting multinational phase 3 clinical trials in Korea and Indonesia to secure an indication for the treatment of gastric ulcers.

Pexuclu is currently available in 30 countries, including Korea. Of these, it has obtained marketing authorization in 16 countries. The product is also set to launch in China soon.

Daewoong Pharmaceutical plans to use this Indonesian approval as a springboard to further accelerate its strategy for the Southeast Asian market and global expansion.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.